MacroGenics Inc (MGNX) stock
MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.20−0.09 (-3.93%)
Close on Nov 13, 2026Market cap $140.14MP/E –Yield –
MacroGenics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
MacroGenics's ebitda for the twelve months ending Sep 30, 2026 was -$59.93M. For fiscal 2025 it was -$65.67M. The highest annual figure on record is $9.21M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$65.67M | – |
| FY2024 | Dec 31, 2024 | -$103.04M | – |
| FY2023 | Dec 31, 2023 | -$158.60M | – |
| FY2022 | Dec 31, 2022 | -$109.55M | – |
| FY2021 | Dec 31, 2021 | -$191.54M | – |
| FY2020 | Dec 31, 2020 | -$119.10M | – |
| FY2019 | Dec 31, 2019 | -$164.88M | – |
| FY2018 | Dec 31, 2018 | -$162.05M | – |
| FY2017 | Dec 31, 2017 | -$14.92M | – |
| FY2016 | Dec 31, 2016 | -$52.43M | – |
| FY2015 | Dec 31, 2015 | -$17.32M | – |
| FY2014 | Dec 31, 2014 | -$36.49M | -2430.3% |
| FY2013 | Dec 31, 2013 | $1.57M | -83.0% |
| FY2012 | Dec 31, 2012 | $9.21M | +45.0% |
| FY2011 | Dec 31, 2011 | $6.35M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.10M | -265.1% |
| Q2 FY2026 | Jun 30, 2026 | -$13.14M | – |
| Q1 FY2026 | Mar 31, 2026 | -$31.75M | – |
| Q4 FY2025 | Dec 31, 2025 | $5.07M | – |
| Q3 FY2025 | Sep 30, 2025 | $12.18M | -78.3% |
| Q2 FY2025 | Jun 30, 2025 | -$41.32M | – |
| Q1 FY2025 | Mar 31, 2025 | -$40.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$50.78M | – |
| Q3 FY2024 | Sep 30, 2024 | $56.03M | – |
| Q2 FY2024 | Jun 30, 2024 | -$56.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$51.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$47.45M | -411.9% |
| Q3 FY2023 | Sep 30, 2023 | -$33.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$35.44M | – |
| Q4 FY2022 | Dec 31, 2022 | $15.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.11M | – |
| Q2 FY2022 | Jun 30, 2022 | -$38.93M | – |
| Q1 FY2022 | Mar 31, 2022 | -$63.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$55.28M | -7778.3% |
| Q3 FY2021 | Sep 30, 2021 | -$50.19M | – |
| Q2 FY2021 | Jun 30, 2021 | -$37.50M | – |
| Q1 FY2021 | Mar 31, 2021 | -$48.56M | – |
| Q4 FY2020 | Dec 31, 2020 | $720.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$33.17M | – |
| Q2 FY2020 | Jun 30, 2020 | -$44.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$42.37M | – |
| Q4 FY2019 | Dec 31, 2019 | -$34.47M | – |
| Q3 FY2019 | Sep 30, 2019 | -$35.31M | – |
| Q2 FY2019 | Jun 30, 2019 | -$50.39M | – |
| Q1 FY2019 | Mar 31, 2019 | -$44.71M | – |
| Q4 FY2018 | Dec 31, 2018 | -$37.79M | -135.5% |
| Q3 FY2018 | Sep 30, 2018 | -$32.28M | – |
| Q2 FY2018 | Jun 30, 2018 | -$43.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$48.87M | – |
| Q4 FY2017 | Dec 31, 2017 | $106.31M | – |
| Q3 FY2017 | Sep 30, 2017 | -$45.82M | – |
| Q2 FY2017 | Jun 30, 2017 | -$39.18M | – |
| Q1 FY2017 | Mar 31, 2017 | -$36.23M | – |
| Q4 FY2016 | Dec 31, 2016 | -$33.26M | – |
See a number that looks wrong?